(Q48434089)

11 February 2018

title

TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors. (English)

1 reference

11 February 2018

author name string

Yang Liu

1

1 reference

11 February 2018

Qing Wang

2

1 reference

11 February 2018

B K Kleinschmidt-DeMasters

3

1 reference

11 February 2018

Alex Franzusoff

4

1 reference

11 February 2018

Ka-yun Ng

5

1 reference

11 February 2018

Kevin O Lillehei

6

1 reference

11 February 2018

publication date

29 August 2006

1 reference

11 February 2018

Journal of Neuro-Oncology

published in

1 reference

11 February 2018

volume

81

1 reference

11 February 2018

page(s)

149-162

1 reference

11 February 2018

issue

2

1 reference

11 February 2018

https://scigraph.springernature.com/pub.10.1007/s11060-006-9222-1

exact match

0 references

cites work

The expression and structure of TGF-beta2 transcripts in rat muscles.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-006-9222-1

Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.

21 January 2018

1 reference

12 December 2020

Influence of PGE2- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes

1 reference

12 December 2020

STUDIES IN IMMUNIZATION AGAINST A TRANSPLANTABLE CEREBRAL MOUSE GLIOMA.

1 reference

12 December 2020

Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes

1 reference

12 December 2020

Effect of irradiation on transforming growth factor-beta secretion by malignant glioma cells.

1 reference

12 December 2020

Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice

1 reference

12 December 2020

Disseminating tumor cells and their interactions with leukocytes visualized in the brain

1 reference

12 December 2020

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

1 reference

12 December 2020

Immunobiology of primary intracranial tumors. Part 5: Correlation of a lymphocyte index and clinical status.

1 reference

12 December 2020

Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2.

1 reference

12 December 2020

The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.

1 reference

12 December 2020

Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.

1 reference

12 December 2020

Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes

1 reference

12 December 2020

Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system

1 reference

12 December 2020

Intrastriatal and intraventricular injections of oligodeoxynucleotides in the rat brain: tissue penetration, intracellular distribution and c-fos antisense effects.

1 reference

12 December 2020

Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients

1 reference

12 December 2020

Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity

1 reference

12 December 2020

Antisense oligodeoxyribonucleotides: stability and distribution after intracerebral injection into rat brain.

1 reference

12 December 2020

Current perspectives in immunotherapy.

1 reference

12 December 2020

Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor

1 reference

12 December 2020

Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors

1 reference

12 December 2020

Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro

1 reference

12 December 2020

Immunization with mutagen-treated (tum-) cells causes rejection of nonimmunogenic rat glioma isografts.

1 reference

12 December 2020

In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers.

1 reference

12 December 2020

Time course analysis and modulating effects of established brain tumor on active-specific immunotherapy

1 reference

12 December 2020

Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha

1 reference

12 December 2020

Expression of the transforming growth factor-beta gene during growth inhibition following polyamine depletion

1 reference

12 December 2020

Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor.

1 reference

12 December 2020

Robust ability of IFN-gamma to upregulate class II MHC antigen expression in tumor bearing rat brains.

1 reference

12 December 2020

Autologous glioma transplantation.

1 reference

12 December 2020

Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness

1 reference

12 December 2020

[Active immunotherapy of cerebral tumor. 20 cases]

1 reference

12 December 2020

Efficacy of intralesionally administered cisplatin-impregnated biodegradable polymer for the treatment of 9L gliosarcoma in the rat.

1 reference

12 December 2020

The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta 2 inhibits the generation of lymphokine-activated killer (LAK) cells.

1 reference

12 December 2020

Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs.

1 reference

12 December 2020

Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review

1 reference

12 December 2020

Use of antisense vectors and oligodeoxynucleotides in neuro-oncology.

1 reference

12 December 2020

Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides.

1 reference

12 December 2020

Modulation of T-cell function by gliomas

1 reference

12 December 2020

Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro

1 reference

12 December 2020

Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes

1 reference

12 December 2020

Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo

1 reference

12 December 2020

Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance

1 reference

12 December 2020

Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

1 reference

12 December 2020

Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2.

1 reference

12 December 2020

Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study.

1 reference

12 December 2020

Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment.

1 reference

12 December 2020

Protease inhibitors interfere with the transforming growth factor-beta-dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression

1 reference

12 December 2020

The therapeutic potential of antisense oligonucleotides

1 reference

12 December 2020

Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells.

1 reference

12 December 2020

Immunity to transplantable nitrosourea-induced neurogenic tumors. II. Immunoprophylaxis of tumors of the brain

1 reference

12 December 2020

Antisense oligonucleotides for central nervous system tumors

1 reference

12 December 2020

Protective effect of immunization with virus-infected glioma cells against intracerebrally implanted glioma in mice

1 reference

12 December 2020

Transforming growth factor beta isoforms in the adult rat central and peripheral nervous system

1 reference

12 December 2020

Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion

1 reference

12 December 2020

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

1 reference

12 December 2020

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

1 reference

12 December 2020

Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth

1 reference

12 December 2020

Gene inhibition using antisense oligodeoxynucleotides

1 reference

12 December 2020

10.1007/S11060-006-9222-1

Identifiers

DOI

1 reference

11 February 2018

PubMed ID

16941073

1 reference

11 February 2018